Payment overview · 2025
General Payments
$12,637.04
114 reported records · 17 companies
Healthcare provider profile · identity verified
Jagat Mehta, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROCHESTER, NY · NPI 1891722062
Verified facts
What the public records show
CMS Open Payments records show Jagat Mehta, MD received $12,637.04 in general payments during 2025 across 114 reported records.
AstraZeneca Pharmaceuticals LP accounted for 83.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $10,556.93 | 83.5% | 29 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $538.28 | 4.3% | 32 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $340.53 | 2.7% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $327.70 | 2.6% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $181.22 | 1.4% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $163.25 | 1.3% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $117.82 | 0.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $105.28 | 0.8% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $96.81 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.08 | 0.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.55 | 0.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.62 | 0.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.24 | 0.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.11 | 0.2% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$20.44 | 0.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.40 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.78 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,220.00 | 6 |
| Food and Beverage | $2,901.16 | 105 |
| Travel and Lodging | $1,515.88 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $10,355.59 | 23 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $340.53 | 15 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $320.42 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $294.66 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $265.60 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $264.91 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $243.62 | 18 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $215.54 | 14 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $181.22 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $163.25 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $117.82 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $105.28 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $96.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $70.43 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.08 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.62 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 110 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 145 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 327 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 83 |
| Losartan Potassium | Losartan Potassium | 248 | 69 |
| Omeprazole | Omeprazole | 235 | 66 |
| Lisinopril | Lisinopril | 193 | 56 |
| Metformin Hcl | Metformin Hcl | 187 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 48 |
| Meloxicam | Meloxicam | 147 | 57 |
| Azithromycin | Azithromycin | 145 | 101 |
| Jardiance | Empagliflozin | 145 | 24 |
| Gabapentin | Gabapentin | 140 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 116 | 31 |
| Eliquis | Apixaban | 110 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 33 |
| Simvastatin | Simvastatin | 88 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 24 |
| Lovastatin | Lovastatin | 73 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | suppressed |
| Amoxicillin | Amoxicillin | 66 | 38 |
| Furosemide | Furosemide | 66 | 27 |
| Allopurinol | Allopurinol | 64 | 19 |
| Metformin Hcl Er | Metformin Hcl | 63 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 17 |
| Carvedilol | Carvedilol | 58 | 17 |
| Alprazolam | Alprazolam | 57 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 16 |
| Ozempic | Semaglutide | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 48 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 11 |
| Trazodone Hcl | Trazodone Hcl | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 44 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Glipizide | Glipizide | 40 | 14 |
| Prednisone | Prednisone | 39 | 19 |
| Spironolactone | Spironolactone | 39 | 14 |
| Cephalexin | Cephalexin | 38 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 29 |
| Methylprednisolone | Methylprednisolone | 34 | 33 |
| Rybelsus | Semaglutide | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 17 |
| Atenolol | Atenolol | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 26 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | 15 |
| Niacin Er | Niacin | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $12,637.04 · 114 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FANAPT, HETLIOZ, INGREZZA, JARDIANCE, Kerendia, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error